Roche secures FDA approval for Tecentriq-based combination to treat NSCLC
Tecentriq binds with PD-L1, a protein expressed on tumour cells and tumour-infiltrating immune cells, to activate T cells…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Dec 19
Tecentriq binds with PD-L1, a protein expressed on tumour cells and tumour-infiltrating immune cells, to activate T cells…
04 Dec 19
AstraZeneca will receive $35m in an upfront payment, in addition to the payments of up to $6m contingent…
The new drug differs from many established acute migraine treatments by lowering blood pressure, rather than raising it
02 Dec 19
ViGeneron will use the funds to advance the development of its next-generation ophthalmic gene therapy pipeline and vector…
28 Nov 19
Incyte is seeking approval of pemigatinib for cholangiocarcinoma on the basis of data from the phase 2 FIGHT-202…
27 Nov 19
The new in-vitro HFpEF model is developed based on Novoheart’s 3-D human ventricular cardiac organoid chamber (hvCOC) technology
26 Nov 19
Risdiplam is an orally administered liquid, designed to increase and sustain SMN protein levels both in the central…
22 Nov 19
IN.PACT AV DCB enables the drug to penetrate deep into the vessel wall to prevent the restenosis and…
22 Nov 19
bNAbs are the antibodies capable of recognising and blocking the entry of different strains of HIV into healthy…
The party's manifesto says every penny spent on privatisation and outsourcing to healthcare companies is a penny less…